Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Tuebingen – page 11

607 clinical trials in Tuebingen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Tuebingen at a glance
607
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

607 trials in Tuebingen

Open in trial search

Acute myeloid leukaemia

Recruiting

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Systemic scleroderma

Recruiting

Study on the Effectiveness and Safety of Efgartigimod PH20 SC for Adults with Systemic Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Breast cancer

Recruiting

Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:F. Hoffmann-La Roche AG

Acute lymphocytic leukaemia

Recruiting

Study on MB-CART2219.1 for Adults and Children with Relapsed or Refractory B-cell Malignancies

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:MB-CART2219.1
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Leber's congenital amaurosis

Recruiting

Study on the Effectiveness and Safety of Sepofarsen for Patients with Leber Congenital Amaurosis Due to a Specific Genetic Mutation

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:SEPOFARSEN
  • Sponsor:Laboratoires Thea

Dry age-related macular degeneration

Recruiting

Study on the Effectiveness and Safety of GAL-101 Eye Drops for Patients with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:SODIUM (R)-2-(2-AMINO-3-(1H-INDOL-3- YL)PROPANAMIDO)-2-METHYLPROPANOATE-PROPAN-2-OL
  • Sponsor:Galimedix Therapeutics Inc.

Non-small cell lung cancer stage IV

Recruiting

Study on Osimertinib and Chemotherapy for Stage IV Non-Small Cell Lung Cancer with Atypical EGFR Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Heidelberg University

Chronic lymphocytic leukaemia+1

Recruiting

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Acute myeloid leukaemia

Recruiting

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Bladder cancer

Recruiting

Study of EG-70 for Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to BCG or High-Risk Patients New to BCG or with Incomplete BCG Treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lauromacrogol 400
  • Sponsor:Engene Inc.

Pancreatic carcinoma metastatic+1

Recruiting

Study of TCR-Modified T Cell Therapy with ANOC-001, ANOC-002, and ANOC-003 for Adults with Advanced Pancreatic Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ANOC-001
  • Sponsor:Anocca AB

Hepatocellular carcinoma+1

Recruiting

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Tuebingen

What the registry says about research in the country

01 Autoimmune & Inflammatory Conditions

Innovative research focusing on cutaneous lupus erythematosus and psoriatic arthritis, evaluating novel therapeutic approaches for managing chronic inflammatory conditions.

  • Lupus skin manifestations
  • Joint inflammation
  • Autoimmune responses

Studies aim to assess new treatment options for improving patient outcomes and quality of life.

02 Oncology Research

Comprehensive studies on various cancer types, including metastatic prostate cancer and basal cell carcinoma, exploring innovative treatment combinations.

  • Advanced cancer therapies
  • Pediatric liver tumors
  • Targeted treatments

Research focuses on improving survival rates and developing more effective treatment strategies.

03 Neurological Disorders

Groundbreaking research in multiple system atrophy and seizure disorders, investigating new therapeutic approaches for complex neurological conditions.

  • Brain function disorders
  • Movement disorders
  • Epilepsy management

Clinical trials aim to enhance treatment options for patients with challenging neurological conditions.

04 Ophthalmology Studies

Advanced research in eye disorders, including Leber congenital amaurosis and geographic atrophy, focusing on innovative treatment approaches.

  • Retinal diseases
  • Visual function
  • Gene therapy

Trials aim to preserve and improve vision in patients with rare and progressive eye conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.